Keep pulling the thread on Dr. Ralph DeFronzo.
Significant weight loss of 20% to 30% of total body weight, such as that induced by GLP-1 agonists, is associated with a loss of muscle mass.
Pharmaceutical companies are actively developing drugs, such as myostatin inhibitors, designed to preserve or increase muscle mass to be used in conjunction with weight loss therapies.
The speaker believes the FDA will not approve a drug for sarcopenia in the elderly based solely on an increase in lean body mass unless it is also accompanied by a demonstrable increase in strength.
The current generation of GLP-1 agonist drugs are considered to be quite safe overall.
The primary side effect of GLP-1 agonist drugs is gastrointestinal toxicity, which necessitates a slow dose titration.
A study of gastric bypass surgery patients showed they lost 33% of their body weight, which was accompanied by a significant decrease in lean body mass.
There are concerns that myostatin inhibitors, a class of drugs being developed to preserve muscle, may have negative cardiovascular side effects.
Myostatin inhibitors as a drug class are currently in Phase 2 of clinical development.
The FDA has established specific criteria that must be met for the approval of drugs intended to treat sarcopenia.
The speaker predicts that the FDA will require drugs that prevent muscle loss during weight reduction to demonstrate an improvement in physical function, not just a change in body composition.
The speaker speculates that the FDA will require a demonstration of improved absolute strength, not relative strength, as a functional endpoint for approving drugs that prevent muscle loss.
The speaker believes the FDA is unlikely to accept improved insulin sensitivity or glucose disposal as a primary approvable endpoint for a muscle-mass-increasing drug.